Esperion Therapeutis.Inc. buy Maxi_Scalibusa
Start price
21.01.18
/
50%
€68.78
Target price
22.05.18
€208.81
Performance (%)
-49.25%
End price
22.05.18
€34.91
Summary
This prediction ended on 22.05.18 with a price of €34.91. The BUY prediction by Maxi_Scalibusa for Esperion Therapeutis.Inc. performed very badly with a performance of -49.25%. Maxi_Scalibusa has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | 0.123% | 0.123% | 105.793% | 42.970% |
| iShares Core DAX® | -0.372% | 8.404% | 6.759% | 47.912% |
| iShares Nasdaq 100 | 2.269% | 15.232% | 36.176% | 94.084% |
| iShares Nikkei 225® | 1.433% | 14.424% | 43.114% | 64.804% |
| iShares S&P 500 | 1.216% | 10.492% | 27.276% | 66.763% |
Comments by Maxi_Scalibusa for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
(Vom Mitglied beendet)